WilmerHale Advises Underwriters in Follow-on Public Offering of Milestone Pharmaceuticals Inc.

WilmerHale Advises Underwriters in Follow-on Public Offering of Milestone Pharmaceuticals Inc.

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the follow-on public offering of 19,666,667 common shares and 3,333,333 pre-funded warrants to purchase common shares of Milestone Pharmaceuticals Inc., a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. The common shares were issued at a public offering price of $1.50 per share and the pre-funded warrants had a public offering price of $1.499 per pre-funded warrant. The gross proceeds to Milestone were $34.5 million, before deducting underwriting discounts, commissions and offering expenses. The offering closed on March 4, 2024.

The WilmerHale team consisted of Lisa Firenze, Ryan Brewer and Molly Nelson, with assistance from Bruce Manheim, Barish Ozdamar and Meghan Walsh.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel